Three-year outcomes of breast intensity-modulated radiation therapy with simultaneous integrated boost.

Purpose: To report our clinical experience using breast intensity-modulated radiation therapy with simultaneous integrated boost (SIB-IMRT).

Methods And Materials: Retrospective review identified 354 Stage 0 to III breast cancer patients treated with SIB-IMRT after conservative surgery between 2003 and 2006. The most common fractionation (89%) simultaneously delivered 1.

Case study of anti-1-amino-3-F-18 fluorocyclobutane-1-carboxylic acid (anti-[F-18] FACBC) to guide prostate cancer radiotherapy target design.

Purpose Of The Report: Anti-1-amino-3-F-18 fluorocyclobutane-1-carboxylic acid (FACBC) is a novel radiotracer, which has shown some promise for use with positron emission tomography (PET)/computed tomography (CT) for visualizing prostate cancer. Here we describe a case of a prostate cancer patient who underwent radiation treatment and had an FACBC scan obtained as part of a pilot study.

Methods: We explored the potential impact of FACBC on treatment planning.

Extra-target doses in children receiving multileaf collimator (MLC) based intensity modulated radiation therapy (IMRT).

Purpose: To investigate the extra-target doses using intensity modulated radiation therapy (IMRT).

Materials And Methods: Thirteen children underwent multileaf collimator (MLC)-based IMRT. Treatment site was head and neck or brain in eight (Group I), trunk in two (Group II), and abdomen/pelvis in three (Group III).